

Data Security & Protection Manager  
 University Hospitals of North Midlands NHS Trust,  
 Newcastle Road,  
 ST4 6QG

20230919 FOI ref 390-2324

19<sup>th</sup> September 2023

FOI Request: Treatment of breast cancer

Dear Data Security & Protection Manager,

I am conducting analysis on the treatment of breast cancer in secondary care and kindly request your help.

I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of Jun 2023 to the end of Aug 2023, or the latest three-month period for which data is available. Please include data for all hospitals in the Trust.

Thank you in advance.

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2023 and end of August 2023?

*Please provide data for the latest 3-month period, if Jun to Aug is not available yet*

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	40
1.2 Alpelisib (Piqray)	0
1.3 Fulvestrant (fulvestrant or Faslodex)	50
1.4 Palbociclib (Ibrance)	45
1.5 Ribociclib (Kisqali)	18

Q2. How many patients received abemaciclib (Verzenios) for **early breast cancer** in the 3 months between the start of June 2023 and end of August 2023?

*Please provide data for the latest 3-month period, if Jun to Aug is not available yet*

Number patients treated
0

Q3. How many patients received abemaciclib (Verzenios) as **adjuvant treatment for early breast cancer** in the 3 months between the start of June 2023 and end of August 2023?

*Please provide data for the latest 3-month period, if Jun to Aug is not available yet*

Number patients treated
<5

Q4. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of June 2023 and end of August 2023?

*Please provide data for the latest 3-month period, if Jun to Aug is not available yet*

Treatment intent	Number patients treated
4.1 Curative	<5
4.2 Palliative	36
4.3 Not known / stated	0

Q5. How many patients were treated with the following medicines in combination in the 3 months between the start of June 2023 and end of August 2023?

*Please provide data for the latest 3-month period, if Jun to Aug is not available yet*

Name of combination or monotherapy	Number patients treated
5.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	20
5.2 Abemaciclib (Verzenios) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	20
5.3 Abemaciclib (Verzenois) + tamoxifen	Unknown as Tamoxifen supplied in Primary Care
5.4 Abemaciclib monotherapy	0
5.5 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)	0
5.6 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	15
5.7 Palbociclib (Ibrance) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	30
5.8 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	<5
5.9 Ribociclib (Kisqali) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	15